COVID-19 response: Belarus earmarks Br68.1m for domestic vaccine production in 2021-2023
<p> MINSK, Nov 5 - PrimePress. Belarus plans to allocate Br68.1 million ($27.7 million at the rate of National Bank of Belarus) for the project to produce the country’s own vaccine against the coronavirus infection on the premises of the pharmaceutical company BelVitunipharm (Vitebsk District) in 2021-2023, in accordance with presidential ordinance #430 of 3 November 2021. </p> <p> </p> <p> The document says that Br11 million ($4.47 million, $1/Br2.4594) will be allocated to finance the construction of the facility, including design and survey work in 2021. </p> <p> </p> <p> The central budget will allocate Br57.1 million ($23.22 million) between 2022 and 2023, including Br50 million ($20.33 million) in 2022 and Br7.1 million ($2.89 million) in 2023. </p> <p> </p> <p> Besides, during the implementation of the investment project, imported technological equipment, components, spare parts, raw materials and supplies are exempted from customs duties and value-added tax. </p> <p> </p> <p> The ordinance came into force on the day it was signed. </p> <p> </p> <p> As previously reported, Belarusian president Alexander Lukashenko on 1 Apr 2021 signed an order to create Belarus’ own vaccine against the coronavirus. On 7 May 2021 Lukashenko said that the country’s own vaccine against COVID-19 had already been obtained “in vitro”. In late July, Belarusian state media reported that a prototype of a domestic vaccine against coronavirus had been created. The development of the prototype was planned to be completed by autumn and put into production in 2022. According to Health Minister Dmitry Pinevich, the Belarusian vaccine against COVID-19 is planned to be released into civilian circulation in 2023. </p> <p> </p> <p> The pharmaceutical company BelVitunipharm (Vitebsk District) was designated as a production site, which will host an investment project to arrange for the manufacture of Belarus’ own vaccine against the COVID-2019 coronavirus in 2021-2023. End </p> <p> </p>
2021-11-06
Primepress
COVID-19 response: Belarus earmarks Br68.1m for domestic vaccine production in 2021-2023
MINSK, Nov 5 - PrimePress. Belarus plans to allocate Br68.1 million ($27.7 million at the rate of National Bank of Belarus) for the project to produce the country’s own vaccine against the coronavirus infection on the premises of the pharmaceutical company BelVitunipharm (Vitebsk District) in 2021-2023, in accordance with presidential ordinance #430 of 3 November 2021.
The document says that Br11 million ($4.47 million, $1/Br2.4594) will be allocated to finance the construction of the facility, including design and survey work in 2021.
The central budget will allocate Br57.1 million ($23.22 million) between 2022 and 2023, including Br50 million ($20.33 million) in 2022 and Br7.1 million ($2.89 million) in 2023.
Besides, during the implementation of the investment project, imported technological equipment, components, spare parts, raw materials and supplies are exempted from customs duties and value-added tax.
The ordinance came into force on the day it was signed.
As previously reported, Belarusian president Alexander Lukashenko on 1 Apr 2021 signed an order to create Belarus’ own vaccine against the coronavirus. On 7 May 2021 Lukashenko said that the country’s own vaccine against COVID-19 had already been obtained “in vitro”. In late July, Belarusian state media reported that a prototype of a domestic vaccine against coronavirus had been created. The development of the prototype was planned to be completed by autumn and put into production in 2022. According to Health Minister Dmitry Pinevich, the Belarusian vaccine against COVID-19 is planned to be released into civilian circulation in 2023.
The pharmaceutical company BelVitunipharm (Vitebsk District) was designated as a production site, which will host an investment project to arrange for the manufacture of Belarus’ own vaccine against the COVID-2019 coronavirus in 2021-2023. End